Mobocertinib
- Generic Name
- Mobocertinib
- Brand Names
- Exkivity
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39N7O4
- CAS Number
- 1847461-43-1
- Unique Ingredient Identifier
- 39HBQ4A67L
- Background
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants causing NSCLC) and are associa...
- Indication
Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04056455
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Hialeah, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04056468
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Hialeah, Florida, United States
A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03811834
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Takeda
- Target Recruit Count
- 53
- Registration Number
- NCT03807778
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
🇯🇵Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.